Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant giredestrant versus physician's choice endocrine monotherapy in ER-positive, HER2-negative early breast cancer
PACTR202108821955108Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of giredestrant in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Primary IDFS. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202108821955108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202108821955108.